GC
Gerald D. Cagle
Director

Gerald D. Cagle insider trades: Aerie Pharmaceuticals (AERI) stock buys and sales

Director, Aerie Pharmaceuticals Last trade May 8, 2020 29 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
13
Open-market trades
since 2014
3
Companies
last trade 2020

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Gerald reports to the SEC

Open-market buys and sales

13 trades reported on SEC Form 4, newest first

DateStockTypeValue
May 8, 2020AERI↓ Sell$76K
Nov 16, 2018AERI↑ Buy$83K
May 25, 2018AERI↑ Buy$49K
May 21, 2018AERI↑ Buy$50K
Mar 22, 2018CLSD↑ Buy$89K
Aug 11, 2017CLSD↑ Buy$35K
May 9, 2017AERI↑ Buy$40K
Apr 19, 2017AERI↑ Buy$83K
Mar 27, 2017CLSD↑ Buy$100K
Mar 16, 2017CLSD↑ Buy$34K
Jun 7, 2016CLSD↓ Sell$14
Aug 28, 2015AERI↑ Buy$85K
May 16, 2014AERI↑ Buy$28K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Gerald D. Cagle's insider trades

Gerald D. Cagle is a director at Aerie Pharmaceuticals (AERI). Since May 16, 2014, Gerald has reported 11 open-market purchases worth $678K and 2 sales worth $76K on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (13 filings), option exercises (3 filings), conversions (2 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AERI insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.